{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,3]],"date-time":"2026-10-03T18:57:53Z","timestamp":1791053873546,"version":"4.1.0"},"reference-count":19,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,8,1]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>Tenofovir alafenamide (TAF), a prodrug of the nucleotide analogue tenofovir (TFV), is an antiretroviral (ARV) agent approved either as a complete regimen [elvitegravir\/cobicistat\/emtricitabine (F)\/TAF, rilpivirine\/F\/TAF, bictegravir\/F\/TAF], or for use with other ARVs (F\/TAF), for treatment of HIV. TAF is a substrate of P-glycoprotein (P-gp) and breast cancer resistance protein (BCRP) transporters. Disposition of TAF may be altered by comedications that can inhibit or induce P-gp or BCRP transporters. The effects of ARVs on the pharmacokinetics of TAF were evaluated in 3 studies.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>Healthy participants received TAF administered alone or with rilpivirine in study 1, with dolutegravir, ritonavir-boosted atazanavir (ATV + RTV), lopinavir (LPV\/RTV), or darunavir (DRV + RTV) in study 2, and with the pharmacokinetic enhancer cobicistat or efavirenz in study 3.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>Across the 3 studies, 98 participants received treatment with TAF and a coadministered agent (n = 10\u201334\/cohort). All study treatments were well tolerated. TAF and TFV exposures were unaffected after co-administration with rilpivirine and dolutegravir. Coadministration with P-gp\/BCRP inhibitors such as cobicistat or PI-based regimens (ATV + RTV, LPV\/r, or DRV + RTV) resulted in a range of 6%\u2013183% increases in TAF and 105%\u2013316% increases in TFV exposure, whereas coadministration with a P-gp inducer, efavirenz, resulted in a 15%\u201324% decrease in TAF and TFV exposure.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Evaluation of the drug interaction between TAF and other commonly prescribed boosted and unboosted ARVs provides characterization of the susceptibility of TAF and\/or TFV pharmacokinetics to inhibitors or inducers of P-gp\/BCRP transporters.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/qai.0000000000001699","type":"journal-article","created":{"date-parts":[[2018,4,11]],"date-time":"2018-04-11T22:47:50Z","timestamp":1523486870000},"page":"465-472","source":"Crossref","is-referenced-by-count":55,"title":["Pharmacokinetics of Tenofovir Alafenamide When Coadministered With Other HIV Antiretrovirals"],"prefix":"10.1097","volume":"78","author":[{"given":"Rebecca","family":"Begley","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moupali","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lijie","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Ling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian P.","family":"Kearney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph M.","family":"Custodio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R2-20230926","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1016\/S0140-6736(15)60616-X","article-title":"Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials","volume":"385","author":"Sax","year":"2015","journal-title":"Lancet."},{"key":"R3-20230926","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1097\/QAI.0000000000000940","article-title":"Brief report: a randomized, double-blind comparison of tenofovir alafenamide versus tenofovir disoproxil fumarate, each coformulated with elvitegravir, cobicistat, and emtricitabine for initial HIV-1 treatment: week 96 results","volume":"72","author":"Wohl","year":"2016","journal-title":"J Acquir Immune Defic Syndr."},{"key":"R4-20230926","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1097\/QAI.0000000000001350","article-title":"Brief report: randomized, double-blind comparison of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF), each coformulated with elvitegravir, cobicistat, and emtricitabine (E\/C\/F) for initial HIV-1 treatment: week 144 results","volume":"75","author":"Arribas","year":"2017","journal-title":"J Acquir Immune Defic Syndr."},{"key":"R5-20230926","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S1473-3099(15)00348-5","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in antiretroviral regimens for virologically suppressed adults with HIV-1 infection: a randomised, active-controlled, multicentre, open-label, phase 3, non-inferiority study","volume":"16","author":"Mills","year":"2016","journal-title":"Lancet Infect Dis."},{"key":"R6-20230926","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/QAI.0000000000000908","article-title":"Switching to tenofovir alafenamide, coformulated with elvitegravir, cobicistat, and emtricitabine, in HIV-infected patients with renal impairment: 48 week results from a single-arm, multi-center, open-label, phase 3 study","volume":"71","author":"Pozniak","year":"2016","journal-title":"J Acquir Immune Defic Syndr."},{"key":"R7-20230926","doi-asserted-by":"crossref","first-page":"e195","DOI":"10.1016\/S2352-3018(17)30031-0","article-title":"Switching from tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"Orkin","year":"2017","journal-title":"Lancet HIV."},{"key":"R8-20230926","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S2352-3018(17)30032-2","article-title":"Switching from efavirenz, emtricitabine, and tenofovir disoproxil fumarate to tenofovir alafenamide coformulated with rilpivirine and emtricitabine in virally suppressed adults with HIV-1 infection: a randomised, double-blind, multicentre, phase 3b, non-inferiority study","volume":"4","author":"DeJesus","year":"2017","journal-title":"Lancet HIV."},{"key":"R9-20230926","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1001\/jama.2016.8900","article-title":"Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2016 recommendations of the International Antiviral Society\u2013USA Panel","volume":"316","author":"G\u00fcnthard","year":"2016","journal-title":"JAMA."},{"key":"R11-20230926","doi-asserted-by":"crossref","first-page":"392","DOI":"10.2165\/00003088-198510050-00002","article-title":"Clinical significance of esterases in man","volume":"10","author":"Williams","year":"1985","journal-title":"Clin Pharmacokinet."},{"key":"R12-20230926","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1016\/S0021-5198(19)31454-4","article-title":"Comparative study of human intestinal and hepatic esterases as related to enzymatic properties and hydrolizing activity for ester-type drugs","volume":"30","author":"Inoue","year":"1980","journal-title":"Jpn J Pharmacol."},{"key":"R13-20230926","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.antiviral.2015.11.009","article-title":"Tenofovir alafenamide: a novel prodrug of tenofovir for the treatment of Human Immunodeficiency Virus","volume":"125","author":"Ray","year":"2016","journal-title":"Antiviral Res."},{"key":"R17-20230926","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1345\/aph.1K615","article-title":"Induction effects of ritonavir: implications for drug interactions","volume":"42","author":"Foisy","year":"2008","journal-title":"Ann Pharmacother."},{"key":"R18-20230926","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1124\/jpet.104.065342","article-title":"HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP\/ABCG2)","volume":"310","author":"Gupta","year":"2004","journal-title":"J Pharmacol Exp Ther."},{"key":"R19-20230926","doi-asserted-by":"crossref","first-page":"2319","DOI":"10.1093\/jac\/dkq324","article-title":"Impact of drug transporters on cellular resistance towards saquinavir and darunavir","volume":"65","author":"K\u00f6nig","year":"2010","journal-title":"J Antimicrob Chemother."},{"key":"R20-20230926","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1124\/dmd.104.002931","article-title":"Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro","volume":"33","author":"Perloff","year":"2005","journal-title":"Drug Metab Dispos."},{"key":"R22-20230926","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/sj.clpt.6100452","article-title":"Effect of an antiretroviral regimen containing ritonavir boosted lopinavir on intestinal and hepatic CYP3A, CYP2D6 and P-glycoprotein in HIV-infected patients","volume":"84","author":"Wyen","year":"2008","journal-title":"Clin Pharmacol Ther."},{"key":"R23-20230926","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ejps.2008.05.007","article-title":"Kinetic analysis of saturable hepatic uptake of digoxin and its inhibition by rifampicin","volume":"34","author":"Weiss","year":"2008","journal-title":"Eur J Pharm Sci."},{"key":"R24-20230926","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1002\/jps.21521","article-title":"Principles, approaches, and challenges for predicting protein aggregation rates and shelf life","volume":"8","author":"Weiss","year":"2009","journal-title":"J Pharm Sci."},{"key":"R29-20230926","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1097\/QAI.0b013e3182965d45","article-title":"Antiviral activity, safety, and pharmacokinetics\/pharmacodynamics of tenofovir alafenamide as 10-day monotherapy in HIV-1-positive adults","volume":"63","author":"Ruane","year":"2013","journal-title":"J Acquir Immune Defic Syndr."}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/00126334-201808010-00015","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,26]],"date-time":"2023-09-26T21:54:37Z","timestamp":1695765277000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201808010-00015"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,8,1]]},"references-count":19,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2018]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0000000000001699","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2018,8,1]]}}}